替罗非班+双抗治疗超溶栓窗急性脑梗死患者效果及对NIHSS、mRS评分影响

Effect of Tirofiban + Dual anti-infarction in Patients with Acute Cerebral Infarction in Ultra-thrombolytic Window and Its Influence on NIHSS and mRS Scores

目的 探讨病发超溶栓窗急性脑梗死患者在采用双抗进行治疗基础上,加用替罗非班效果,及对NIHSS、m RS评分所产生的影响。方法 选取该院2019年1月—2021年1月收治的60例病发超溶栓窗急性脑梗死患者为研究对象,采用数字表抽取法予以随机分组,即对照组(单纯应用双抗治疗方案)和观察组(林柯彤替罗非班)各30例。对比两组临床治疗总有效率、神经功能缺损程度及病情转归程度、颅内动脉血流动力学指标、不良反应发生率。结果 观察组总有效率为90.00%,高于对照组66.67%,差异有统计学意义(χ^(2)=4.812,P=0.028)。治疗前,两组美国国立卫生研究院卒中量表(NIHSS)评分、修正Rankin量表(mRS)评分差异无统计学意义(P>0.05)。治疗后,观察组NIHSS评分、mRS评分低于对照组,差异有统计学意义(t=9.581、3.880,P<0.001)。治疗前,两组颅内动脉血流学指标对比差异无统计学意义(P>0.05)。治疗后,观察组颅内动脉血流动力学指标优于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为6.67%,低于对照组,差异有统计学意义(χ^(2)=5.455,P<0.005)。结论 针对临床收治的超溶栓窗急性脑梗死患者,在双抗基础上,取替罗非班方案加用治疗,可增强临床治疗效果,改善神经功能缺损程度,促使病程转归,且可改善颅内动脉血流动力学指标,并可防范不良反应的发生,开展价值十分突出。

Objective To investigate the effect of tirofiban in addition to tirofiban on the basis of dual-antibody therapy in patients with acute cerebral infarction at the ultra-thrombolytic window,and its effect on NIHSS and mRS scores.Methods A total of 60 patients with acute cerebral infarction in the ultra-thrombolytic window who were treated in the hospital from January 2019 to January 2021 were selected and randomly divided into groups by the digital table extraction method,namely the control group(single application of dual-antibody therapy) and the observation group(to take tirofiban for additional use) 30 cases each.The total effective rate of clinical treatment,degree of neurological deficit,degree of disease outcome,intracranial arterial hemodynamics indexes,and incidence of adverse reactions were compared between the two groups.Results The total effective rate was 90.00% in the observation group,higher than 66.67% in the control group,and the difference was statistically significant(χ^(2)=4.812,P=0.028).Before treatment,there was no statistically significant difference in the National Institutes of Health Stroke Scale(NIHSS) score and modified Rankin Scale(mRS) score between the two groups(P>0.05).After treatment,the NIHSS score and m RS score of the observation group were lower than those of the control group,and the difference was statistically significant(t=9.581,3.880,P<0.001).Before treatment,there was no statistically significant difference in intracranial arterial hemodynamics indexes between the two groups(P>0.05).After treatment,the intracranial arterial hemodynamics indexes in the observation group were better than those in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 6.67%,which was lower than that in the control group,and the difference was statistically significant(χ^(2)=5.455,P<0.05).Conclusion For the clinically treated patients with acute cerebral infarction in the ultra-thrombolytic window,the addition of tirofiban regimen on the basis of double antibody therapy can enhance the clinical treatment effect,improve the degree of neurological deficit,and promote the course of the disease,and can improve intracranial arterial hemodynamic indicators,and can prevent the occurrence of adverse reactions,the development value is very prominent.